The Food and Drug Administration (FDA) has cleared a 3-minute session protocol, Theta Burst Stimulation, for the NBT System (Nexstim) used to treat major depressive disorder (MDD). Previously, the standard protocol time for the therapy was 37 minutes.
The Theta Burst Stimulation is a newer form of repetitive transcranial magnetic stimulation that allows for navigation of stimulation to specific areas of the patient’s brain, according to the Company.
The new 3-minute NBT protocol was approved based on results from a study of 414 patients with treatment-resistant depression, which found that intermittent Theta Burst Stimulation was non-inferior to high-frequency transcranial magnetic stimulation.
The Company believes that the shorter protocol will increase ease of use for the NBT system.
For more information visit Nexstim.com.
This article originally appeared on MPR